Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast cancer, correlating with poor prognosis.
• Existing therapies for HER2+ breast cancer face challenges with side effects and resistance.
• Tumor-targeting peptides offer promising properties for targeted cancer therapy.

Purpose of the Study:

• To develop and evaluate fluorescently-labeled HER2-specific peptides and their combined analogues for targeting HER2.
• To investigate the binding affinity and specificity of these peptides on breast cancer cell lines with varying HER2 expression.
• To explore the potential of these conjugates for diagnostic and therapeutic applications in HER2+ breast cancer.

Main Methods:

• Synthesis and fluorescent labeling of HER2-specific peptides and their combined analogues.
• In vitro investigation on breast cancer cell lines with differential HER2 expression.
• Confirmation of extracellular localization and specificity using flow cytometry and confocal microscopy.
• Secondary structure prediction to correlate peptide structure with receptor recognition.

Main Results:

• A novel, combined HER2 binding conjugate was successfully developed.
• The conjugate demonstrated high affinity and specificity for HER2-overexpressing cells.
• Extracellular localization and specificity were confirmed through advanced imaging and cytometry techniques.
• The α-helical content of the peptides was found to be associated with HER2 recognition.

Conclusions:

• The developed HER2-specific conjugate is a promising tool for targeting HER2-overexpressing breast cancer cells.
• Its high affinity and specificity suggest potential for future diagnostic and drug-targeting applications.
• Understanding the structural basis of peptide-receptor interaction can guide the design of improved targeted therapies.